Authors:
Liese Barbier, MSc, PharmD, PhD, KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium
Catarina Lopes Pereira, MSc, PharmD, Chair, ISPOR Biosimilar Special Interest Group, Brussels, Belgium
Teresa Barcina Lacosta, MSc, PharmD, PhD Candidate, KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium
Contributors:
Aurelio Arias, MSc, IQVIA, Zurich, Switzerland
Sue Caleo-Naeyaert, MCom, PharmD, Independent consultant, Health Economics, Global Market Access, and Pricing, New South Wales, Australia
Dalia Dawoud, MSc, PhD, National Institute for Health and Care Excellence (NICE), London, UK; Cairo University, Faculty of Pharmacy, Cairo, Egypt
András Inotai, PharmD, PhD, Semmelweis University, Center for Health Technology Assessment, Budapest, Hungary
Manthan Janodia, MPH, PhD, Department of Pharmacy Management, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India
Patel Jayeshkumar, Alexion Pharmaceuticals, Inc., Connecticut, USA
Chia Jie, University of Utah College of Pharmacy, Utah, USA
Amir Nazari, Novartis Oncology, Tehran Province, Iran
Chaudhari Vivek, PhD, EMD Serono, Inc., Massachusetts, USA
John Whalen, BS, BSc, MBA, Pharming Group N.V., London, UK